
2020 PROGRAM GUIDE





Creating a healthier Hawai'i

LETTER TO COLLEAGUES 3	3
PROGRAM GUIDE FOR PROVIDERS	
Overview	ļ
Quality Performance Program 4	ļ
Shared Savings Program 4	ļ
Individual vs. Group Provider Participation 4	ļ
Measurement Period	ļ
POSSIBLE POINTS BY SPECIALTY	
Quality Performance Program (QPP)	7
Shared Savings Program (SSP)	3
QUALITY PERFORMANCE AND SHARED SAVINGS PROGRAM	
Quality Performance Program (QPP)	
Criteria for Receiving Incentives	1

	Criteria for Receiving Incentives	14
S	hared Savings Program (SSP)	
	Criteria for Receiving Incentives	14

MEASURES IN BOTH QPP AND SSP

Attendance at HHP Annual Membership Meeting	16
HHP Learning Modules	17
Participation in HHP Clinical Workgroups	18

QUALITY PERFORMANCE PROGRAM MEASURES

Advance Care Planning in the Ambulatory Setting 22	2
Advance Care Planning in the Inpatient Setting 24	4
Enhanced Recovery After Surgery (ERAS) Order Sets	5
Hospital Acquired Harm	6
Obstructive Sleep Apnea Screening 27	7
Oncology Staging: Clinical	8
Perioperative Surgical Home: Surgeon Participation	1
Sepsis and Septic Shock: Management Bundle (Composite Measure)	2
Vermont Oxford Network for VLBW and Expanded Database Measures 34	4

SHARED SAVINGS PROGRAM MEASURES

APPENDIX

Appendix E: Compensating Specialists	
Shared Savings Program	73

COLLEAGUES:

In 2014, Hawai'i Health Partners was formed giving impetus to the healthcare transformation movement in Hawai'i. Six years later, with over 130,000 patient lives and a membership of more than 900 healthcare providers, we are still the leader of value-based healthcare and advocates of the quadruple aim framework in Hawai'i – improving patient experience (quality and satisfaction); improving population health; decreasing health care costs; and increasing care team wellbeing.

Now in our third year of moving toward global capitation and second year of the three year Accountable Care Agreement (ACA), the design of this year's Quality Performance and Shared Savings Programs (QPP/ SSP) is important to our success in value-based care. An expanded and improved QPP/SSP has been created through the collaborative efforts of the Finance and Quality & Clinical Integration Committees as well as the Metrics Subcommittee, the physician-led HHP Board of Managers, HHP administration, and with input from the membership at large.

It is our pleasure to present the 2020 Program Guide, developed with your feedback along with these guiding principles:

- Clinically meaningful and impactful measures
- Broad participation for members
- Promoting appropriate, high-quality care
- Improving patient access
- Developing more efficient processes for better patient outcomes
- Sharing provider knowledge across referring specialties

This year's Program Guide spans 78 specialties and clinical practice areas for Primary Care and specialists, with more than 30 measures – opportunities to earn points and deliver high-quality and high-value care to your patients. Over the next year, we ask that you take advantage of the QPP/SSP and use it as a conduit for driving change.

You are the forward-thinkers and decision-makers in our journey to transform health care. Your engagement determines what it looks like for providers to own their future, and to that end, we will continue to be your partners, in the thick of it.

Thank you for your commitment to transform healthcare in Hawai'i.

Sincerely,

Gerard Livaudais, MD, MPH, FACP

Vice President

Hawai'i Health Partners Overview

As the state's first physician-led Accountable Care Organization (ACO), Hawai'i Health Partners (HHP) manages the integration of a high-performing network of providers, facilities, and hospitals; aligned to provide patient-centered, high-quality care. We are a physicianled ACO; our goal is to improve health care in Hawai'i by focusing on value-based care, increasing efficiency and developing a network that provides highly coordinated care with optimal patient health outcomes.

To engage individual providers under these goals, Hawai'i Health Partners has two performance programs, the Quality Performance and Shared Savings Programs, with potential for incentive payments. Each has unique characteristics and methodologies for how the programs are funded and rewards are distributed.

Quality Performance Program

The Quality Performance Program (QPP) is designed to engage and recognize providers who contribute to achieving quality performance goals in the inpatient setting benefitting the care of HHP's attributed members.

Shared Savings Program

The Shared Savings Program (SSP) is designed to engage and recognize providers who improve population health by contributing to quality and appropriate, efficient care. The combined effect improves quality and slows unnecessary growth in the medical cost trend for HHP's attributed members.

Individual vs. Group Provider Participation

Individual performance and incentives will be calculated for all **eligible** HHP providers, regardless of whether the provider joins as an individual or as a member of a group. For providers participating as members of a group, allocation of incentives and related funds will be made to the group. It is the group's discretion as to how those funds are distributed to its providers.

Measurement Period

Both programs are annual programs starting on January 1, 2020 and ending December 31, 2020. Quarterly interim reports are provided throughout the year. However, final eligibility for incentive payments and final performance scores are determined after the end of the calendar year. Payment will be made following determination of fund availability. For more information, contact Info@hawaiihealthpartners.org.

POINTS BY SPECIALTY QUALITY PERFORMANCE PROGRAM

Page	16	17	18	22	24	25	26	27	28	31	32	34
	Attendance at HHP Annual Membership Meeting	HHP Learning Modules (points per completed module)	Participation in HHP Clinical Workgroups (points per workgroup)	Advance Care Planning in the Ambulatory Setting	Advance Care Planning in the Inpatient Setting	Enhanced Recovery After Surgery (ERAS) Order Sets	Hospital Acquired Harm	Obstructive Sleep Apnea Screening	Oncology Staging: Clinical	Perioperative Surgical Home: Surgeon Participation	Sepsis and Septic Shock: Management Bundle	Vermont Oxford Network for VLBW and Expanded Database Measures
PRIMARY CARE (carrying a panel)												
Advanced Practice RN (APRN) carrying a primary care panel	0.5	0.25	1	1								
Family Medicine (PCP)	0.5	0.25	1	1								
General Practice (PCP)	0.5	0.25	1	1								
Internal Medicine (PCP)	0.5	0.25	1	1								
Pediatrics (PCP)	0.5	0.25	1									
SPECIALIST												
Adolescent Medicine (non-PCP)	0.5	0.25	1									
Allergy & Immunology	0.5	0.25	1									
Anesthesiology	0.5	0.25	1			1	1	1				
Cardiac Electrophysiology	0.5	0.25	1				1					
Cardiology	0.5	0.25	1				1					
Clinical Psychology	0.5	0.25	1									
Critical Care Medicine	0.5	0.25	1		1		1				2	
Dermatology	0.5	0.25	1									
Dermatopathology	0.5	0.25	1									
Developmental-Behavioral Peds	0.5	0.25	1									
Diagnostic Radiology	0.5	0.25	1									
Emergency Medicine	0.5	0.25	1				1				2	
Endocrinology	0.5	0.25	1									
Family Medicine (non-PCP)	0.5	0.25	1									
Gastroenterology	0.5	0.25	1				1		1			
General Practice (non-PCP)	0.5	0.25	1									
General Surgery	0.5	0.25	1			1	1		1	1	1	
Geriatric Medicine	0.5	0.25	1	1								
Gynecologic Oncology	0.5	0.25	1			1	1		1	1	1	

POINTS BY SPECIALTY QUALITY PERFORMANCE PROGRAM

Page	16	17	18	22	24	25	26	27	28	31	32	34
	Attendance at HHP Annual Membership Meeting	HHP Learning Modules (points per completed module)	Participation in HHP Clinical Workgroups (points per workgroup)	Advance Care Planning in the Ambulatory Setting	Advance Care Planning in the Inpatient Setting	Enhanced Recovery After Surgery (ERAS) Order Sets	Hospital Acquired Harm	Obstructive Sleep Apnea Screening	Oncology Staging: Clinical	Perioperative Surgical Home: Surgeon Participation	Sepsis and Septic Shock: Management Bundle	Vermont Oxford Network for VLBW and Expanded Database Measures
Gynecology	0.5	0.25	1			1	1		1	1	1	
Hematology/Oncology	0.5	0.25	1				1		1			
Hospice and Palliative Medicine	0.5	0.25	1		1		1					
Hospitalist - Family Medicine	0.5	0.25	1		1		1				2	
Hospitalist - Internal Medicine	0.5	0.25	1		1		1				2	
Hospitalist - Pediatrics	0.5	0.25	1				1				2	
Infectious Disease	0.5	0.25	1				1					
Internal Medicine (non-PCP)	0.5	0.25	1									
Interventional Radiology	0.5	0.25	1				1					
Maternal & Fetal Medicine	0.5	0.25	1				1					
Medical Genetics	0.5	0.25	1									
Neonatology	0.5	0.25	1				1					2.5
Nephrology	0.5	0.25	1				1					
Neurology	0.5	0.25	1				1					
Neuroradiology	0.5	0.25	1									
Neurosurgery	0.5	0.25	1				1		1	1	1	
Nuclear Medicine	0.5	0.25	1									
Obstetrics & Gynecology	0.5	0.25	1			1	1		1	1	1	
Occupational Medicine	0.5	0.25	1									
Ophthalmology	0.5	0.25	1				1		1	1	1	
Orthopedic Surgery	0.5	0.25	1			1	1		1	1	1	
Otolaryngology	0.5	0.25	1				1		1	1	1	
Pathology	0.5	0.25	1									
Pediatric Cardiology	0.5	0.25	1				1					
Pediatric Critical Care	0.5	0.25	1				1				2	
Pediatric Emergency Medicine	0.5	0.25	1				1				2	
Pediatric Endocrinology	0.5	0.25	1				1					

POINTS BY SPECIALTY QUALITY PERFORMANCE PROGRAM

Page	16	17	18	22	24	25	26	27	28	31	32	34
	Attendance at HHP Annual Membership Meeting	HHP Learning Modules (points per completed module)	Participation in HHP Clinical Workgroups (points per workgroup)	Advance Care Planning in the Ambulatory Setting	Advance Care Planning in the Inpatient Setting	Enhanced Recovery After Surgery (ERAS) Order Sets	Hospital Acquired Harm	Obstructive Sleep Apnea Screening	Oncology Staging: Clinical	Perioperative Surgical Home: Surgeon Participation	Sepsis and Septic Shock: Management Bundle	Vermont Oxford Network for VLBW and Expanded Database Measures
Pediatric Gastroenterology	0.5	0.25	1				1		1			
Pediatric Hematology/Oncology	0.5	0.25	1				1		1			
Pediatric Infectious Diseases	0.5	0.25	1				1					
Pediatric Nephrology	0.5	0.25	1				1					
Pediatric Neurology	0.5	0.25	1				1		1			
Pediatric Pulmonology	0.5	0.25	1				1					
Pediatric Rheumatology	0.5	0.25	1									
Pediatric Sports Medicine	0.5	0.25	1									
Pediatric Surgery	0.5	0.25	1			1	1		1	1	1	
Pediatric Urology	0.5	0.25	1				1		1	1	1	
Pediatrics (non-PCP)	0.5	0.25	1									
Physical Medicine & Rehab	0.5	0.25	1									
Plastic Surgery	0.5	0.25	1				1		1	1	1	
Podiatry	0.5	0.25	1				1		1	1	1	
Psychiatry	0.5	0.25	1									
Pulmonology	0.5	0.25	1				1					
Radiation Oncology	0.5	0.25	1									
Repro Endocrin/Infertility	0.5	0.25	1									
Rheumatology	0.5	0.25	1									
Sleep Medicine	0.5	0.25	1									
Sports Medicine	0.5	0.25	1									
Surgical Oncology	0.5	0.25	1			1	1		1	1	1	
Thoracic Surgery	0.5	0.25	1				1		1	1	1	
Urgent Care/Walk-In	0.5	0.25	1									
Urogynecology & Pelvic Reconstruction	0.5	0.25	1			1	1		1	1	1	
Urology	0.5	0.25	1				1		1	1	1	
Vascular Surgery	0.5	0.25	1				1		1	1	1	

Page	16	17	18	36	38	41	42	44	47	51	53	55
	Attendance at HHP Annual Membership Meeting	HHP Learning Modules (points per completed module)	Participation in HHP Clinical Workgroups (points per workgroup)	Adolescent HPV Immunization	Adolescent Immunizations	Adolescent Well-Care Visit	Avoidable ED Utilization	Controlling High Blood Pressure	Diabetes Bundle - Primary Care	Diabetes: Eye Exam - Specialists	Diabetes: Hemoglobin A1c (HbA1c) Control - Specialists	Diabetes: Hemoglobin A1c (HbA1c) Lab Completion Rate
PRIMARY CARE (carrying a panel)												
Advanced Practice RN (APRN) carrying a primary care panel	0.5	0.25	1	2	2	2	1	1.5	9			2
Family Medicine (PCP)	0.5	0.25	1	2	2	2	1	1.5	9			2
General Practice (PCP)	0.5	0.25	1	2	2	2	1	1.5	9			2
Internal Medicine (PCP)	0.5	0.25	1				1	1.5	9			2
Pediatrics (PCP)	0.5	0.25	1	2	2	2	1					2
SPECIALIST												
Adolescent Medicine (non-PCP)	0.5	0.25	1				1					
Allergy & Immunology	0.5	0.25	1				1					
Anesthesiology	0.5	0.25	1				1					
Cardiac Electrophysiology	0.5	0.25	1				1					
Cardiology	0.5	0.25	1				1	1.5				
Clinical Psychology	0.5	0.25	1				1					
Critical Care Medicine	0.5	0.25	1				1					
Dermatology	0.5	0.25	1				1					
Dermatopathology	0.5	0.25	1				1					
Developmental-Behavioral Peds	0.5	0.25	1				1					
Diagnostic Radiology	0.5	0.25	1									
Emergency Medicine	0.5	0.25	1				1					
Endocrinology	0.5	0.25	1				1	1.5		1.5	3	
Family Medicine (non-PCP)	0.5	0.25	1				1					
Gastroenterology	0.5	0.25	1				1					
General Practice (non-PCP)	0.5	0.25	1				1					
General Surgery	0.5	0.25	1				1					
Geriatric Medicine	0.5	0.25	1				1					
Gynecologic Oncology	0.5	0.25	1				1					
Gynecology	0.5	0.25	1				1					
Hematology/Oncology	0.5	0.25	1				1					
Hospice and Palliative Medicine	0.5	0.25	1				1					

Page	56	57	58	59	60	62	63	64	65	66	67	68
	End of Life Care for Cancer Patients	Mammogram Imaging Callback Rates	National Imaging Associates (NIA) / Magellan Prior Authorizations	NSAID Utilization in CKD Patients	Osteoporosis Management in Women Who Had a Fracture	Postpartum Care	Prenatal Care	Provider Use of Epic eConsults	Provider Use of MyChart eVisits	Referral of High Risk Patients to HHP Complex Care Program	Use of High Risk Medications in the Elderly	Use of HHP Dashboard
PRIMARY CARE (carrying a panel)		1	<u> </u>		<u> </u>				1	11		
Advanced Practice RN (APRN) carrying a primary care panel			1	1	1	1	1	1	1	1	1	1
Family Medicine (PCP)			1	1	1	1	1	1	1	1	1	1
General Practice (PCP)			1	1	1	1	1	1	1	1	1	1
Internal Medicine (PCP)			1	1	1	1	1	1	1	1	1	1
Pediatrics (PCP)			1	1		1	1	1	1			1
SPECIALIST												
Adolescent Medicine (non-PCP)			1	1				1			1	
Allergy & Immunology			1	1				1			1	
Anesthesiology				1				1			1	
Cardiac Electrophysiology			1	1				1			1	
Cardiology			1	1				1			1	
Clinical Psychology			1	1				1			1	
Critical Care Medicine				1				1			1	
Dermatology			1	1				1			1	
Dermatopathology			1	1				1			1	
Developmental-Behavioral Peds			1	1				1			1	
Diagnostic Radiology		1						1				
Emergency Medicine				1				1			1	
Endocrinology			1	1				1			1	
Family Medicine (non-PCP)			1	1				1			1	
Gastroenterology			1	1				1			1	
General Practice (non-PCP)			1	1				1			1	
General Surgery			1	1				1			1	
Geriatric Medicine			1	1				1			1	
Gynecologic Oncology			1	1				1			1	
Gynecology			1	1		1	1	1			1	
Hematology/Oncology	1		1	1				1			1	
Hospice and Palliative Medicine			1	1				1			1	

Page	16	17	18	36	38	41	42	44	47	51	53	55
	Attendance at HHP Annual Membership Meeting	HHP Learning Modules (points per completed module)	Participation in HHP Clinical Workgroups (points per workgroup)	Adolescent HPV Immunization	Adolescent Immunizations	Adolescent Well-Care Visit	Avoidable ED Utilization	Controlling High Blood Pressure	Diabetes Bundle - Primary Care	Diabetes: Eye Exam - Specialists	Diabetes: Hemoglobin A1c (HbA1c) Control - Specialists	Diabetes: Hemoglobin A1c (HbA1c) Lab Completion Rate
Hospitalist - Family Medicine	0.5	0.25	1				1					
Hospitalist - Internal Medicine	0.5	0.25	1				1					
Hospitalist - Pediatrics	0.5	0.25	1				1					
Infectious Disease	0.5	0.25	1				1					
Internal Medicine (non-PCP)	0.5	0.25	1				1					
Interventional Radiology	0.5	0.25	1				1					
Maternal & Fetal Medicine	0.5	0.25	1				1					
Medical Genetics	0.5	0.25	1									
Neonatology	0.5	0.25	1				1					
Nephrology	0.5	0.25	1				1	1.5				
Neurology	0.5	0.25	1				1					
Neuroradiology	0.5	0.25	1									
Neurosurgery	0.5	0.25	1				1					
Nuclear Medicine	0.5	0.25	1									
Obstetrics & Gynecology	0.5	0.25	1				1					
Occupational Medicine	0.5	0.25	1				1					
Ophthalmology	0.5	0.25	1				1			1.5		
Orthopedic Surgery	0.5	0.25	1				1					
Otolaryngology	0.5	0.25	1				1					
Pathology	0.5	0.25	1									
Pediatric Cardiology	0.5	0.25	1				1					
Pediatric Critical Care	0.5	0.25	1				1					
Pediatric Emergency Medicine	0.5	0.25	1				1					
Pediatric Endocrinology	0.5	0.25	1				1					
Pediatric Gastroenterology	0.5	0.25	1				1					
Pediatric Hematology/Oncology	0.5	0.25	1				1					
Pediatric Infectious Diseases	0.5	0.25	1				1					
Pediatric Nephrology	0.5	0.25	1				1					
Pediatric Neurology	0.5	0.25	1				1					

Page	56	57	58	59	60	62	63	64	65	66	67	68
	End of Life Care for Cancer Patients	Mammogram Imaging Callback Rates	National Imaging Associates (NIA) / Magellan Prior Authorizations	NSAID Utilization in CKD Patients	Osteoporosis Management in Women Who Had a Fracture	Postpartum Care	Prenatal Care	Provider Use of Epic eConsults	Provider Use of MyChart eVisits	Referral of High Risk Patients to HHP Complex Care Program	Use of High Risk Medications in the Elderly	Use of HHP Dashboard
Hospitalist - Family Medicine				1				1			1	
Hospitalist - Internal Medicine				1				1			1	
Hospitalist - Pediatrics				1				1			1	
Infectious Disease			1	1				1			1	
Internal Medicine (non-PCP)			1	1				1			1	
Interventional Radiology								1				
Maternal & Fetal Medicine			1	1				1				
Medical Genetics								1				
Neonatology			1	1				1			1	
Nephrology			1	1				1			1	
Neurology			1	1				1			1	
Neuroradiology								1				
Neurosurgery			1	1				1			1	
Nuclear Medicine								1				
Obstetrics & Gynecology			1	1		1	1	1			1	
Occupational Medicine				1				1			1	
Ophthalmology			1	1				1			1	
Orthopedic Surgery			1	1				1			1	
Otolaryngology			1	1				1			1	
Pathology								1				
Pediatric Cardiology			1	1				1			1	
Pediatric Critical Care			1	1				1			1	
Pediatric Emergency Medicine			1	1				1			1	
Pediatric Endocrinology			1	1				1			1	
Pediatric Gastroenterology			1	1				1			1	
Pediatric Hematology/Oncology	1		1	1				1			1	
Pediatric Infectious Diseases			1	1				1			1	
Pediatric Nephrology			1	1				1			1	
Pediatric Neurology			1	1				1			1	

	Page	16	17	18	36	38	41	42	44	47	51	53	55
		Attendance at HHP Annual Membership Meeting	HHP Learning Modules (points per completed module)	Participation in HHP Clinical Workgroups (points per workgroup)	Adolescent HPV Immunization	Adolescent Immunizations	Adolescent Well-Care Visit	Avoidable ED Utilization	Controlling High Blood Pressure	Diabetes Bundle - Primary Care	Diabetes: Eye Exam - Specialists	Diabetes: Hemoglobin A1c (HbA1c) Control - Specialists	Diabetes: Hemoglobin A1c (HbA1c) Lab Completion Rate
Pediatric Pulmonology		0.5	0.25	1				1					
Pediatric Rheumatology		0.5	0.25	1				1					
Pediatric Sports Medicine		0.5	0.25	1				1					
Pediatric Surgery		0.5	0.25	1				1					
Pediatric Urology		0.5	0.25	1				1					
Pediatrics (non-PCP)		0.5	0.25	1				1					
Physical Medicine & Rehab		0.5	0.25	1				1					
Plastic Surgery		0.5	0.25	1				1					
Podiatry		0.5	0.25	1				1					
Psychiatry		0.5	0.25	1				1					
Pulmonology		0.5	0.25	1				1					
Radiation Oncology		0.5	0.25	1				1					
Repro Endocrin/Infertility		0.5	0.25	1				1					
Rheumatology		0.5	0.25	1				1					
Sleep Medicine		0.5	0.25	1				1					
Sports Medicine		0.5	0.25	1				1					
Surgical Oncology		0.5	0.25	1				1					
Thoracic Surgery		0.5	0.25	1				1					
Urgent Care/Walk-In		0.5	0.25	1				1					
Urogynecology & Pelvic Reconstruction		0.5	0.25	1				1					
Urology		0.5	0.25	1				1					
Vascular Surgery		0.5	0.25	1				1					

	Page	56	57	58	59	60	62	63	64	65	66	67	68
		End of Life Care for Cancer Patients	Mammogram Imaging Callback Rates	National Imaging Associates (NIA) / Magellan Prior Authorizations	NSAID Utilization in CKD Patients	Osteoporosis Management in Women Who Had a Fracture	Postpartum Care	Prenatal Care	Provider Use of Epic eConsults	Provider Use of MyChart eVisits	Referral of High Risk Patients to HHP Complex Care Program	Use of High Risk Medications in the Elderly	Use of HHP Dashboard
Pediatric Pulmonology				1	1				1			1	
Pediatric Rheumatology				1	1				1			1	
Pediatric Sports Medicine				1	1				1			1	
Pediatric Surgery				1	1				1			1	
Pediatric Urology				1	1				1			1	
Pediatrics (non-PCP)				1	1				1			1	
Physical Medicine & Rehab				1	1				1			1	
Plastic Surgery				1	1				1			1	
Podiatry				1	1				1			1	
Psychiatry				1	1				1			1	
Pulmonology				1	1				1			1	
Radiation Oncology				1	1				1			1	
Repro Endocrin/Infertility				1	1				1				
Rheumatology				1	1				1			1	
Sleep Medicine				1	1				1			1	
Sports Medicine				1	1				1			1	
Surgical Oncology				1	1				1			1	
Thoracic Surgery				1	1				1			1	
Urgent Care/Walk-In				1	1				1			1	
Urogynecology & Pelvic Reconstruction				1	1				1			1	
Urology				1	1				1			1	
Vascular Surgery				1	1				1			1	



QUALITY PERFORMANCE PROGRAM

A provider is eligible to receive incentives under this program if all of the following criteria have been met:

- 1. The provider is a credentialed, participating provider of HHP for at least 90 days of the measurement year.
- 2. The collective HPH hospital system quality performance threshold was achieved for the measurement year.
- 3. The individual HPH hospital performance threshold was achieved for the HPH hospital at which the provider is associated, based on medical staff membership. In the event a provider is a member of the medical staff of more than one HPH hospital, the provider will be asked to designate one hospital where the majority of his or her work is done. Providers may contact HHP to change their primary facility. This designation is reviewed during the credentialing and reappointment process, and is subject to approval by the HHP Board of Managers. Measure eligibility will be based on the provider's primary facility during the majority of the measurement period.
- 4. The provider meets the quality thresholds for those applicable measures, based on the provider's specialty or clinical practice area and the minimum patient threshold for measures with defined thresholds.

SHARED SAVINGS PROGRAM

A provider is eligible to receive incentives under this program if all of the following criteria have been met:

- 1. The provider is a credentialed, participating provider of HHP for at least 90 days of the measurement year.
- 2. Medical Cost Trend performance has been lower than target, resulting in the funding of the bonus pool for the Shared Savings Program.
- 3. The provider meets the quality thresholds for applicable measures, based on the provider's specialty or clinical practice area and the minimum patient threshold for measures with defined thresholds.
 - a. For PCPs, the Shared Savings payout will be calculated based on the points earned multiplied by either the number of attributed lives at the end of the measurement year or the date of their departure from HHP in the event of separation.
 - b. For Specialists, the Shared Savings payout will be calculated based on the points earned multiplied by their specialty tier. Specialty tiers are set according to impact on Medical Cost Trend.

MEASURES IN BOTH QUALITY PERFORMANCE AND SHARED SAVINGS PROGRAMS QPP / SSP

PP / SSP	
ENGAGEMENT	ATTENDANCE AT HHP ANNUAL MEMBERSHIP MEETING
Measure Objective	Encourage provider engagement and provide opportunities for collaboration and networking among HHP members; share information about HHP programs, initiatives, and physician-led enterprises.
Description	Attendance at and participation in the HHP Annual Membership Meeting
Points	Total Points: 1 • QPP: 0.5 point • SSP: 0.5 point
Program	QPP & SSP
Inclusion	All eligible HHP members
Exclusion	N/A
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	Arrival and registration by the designated time. An exception will be made for those providers with late attendance or absence due to unavoidable clinical duties. Prior notification to Info@Hawaiihealthpartners.org is required for late attendance or absence due to unavoidable clinical duties. Scheduled viewings will be made available at a future date for those providers who were absent due to unavoidable clinical duties. Available dates and times of the scheduled viewings will be sent to those who provide prior notification. Points will be awarded upon attendance of the meeting or scheduled viewing.
Eligible Members	All eligible HHP embers

ENGAGEMENT

Measure Objective	Provide an educational resource to support implementation of care improvement processes that target care quality, outcomes, and efficiency
Description	Completion of HHP learning modules
Points	Completing one HHP learning module earns 0.25 QPP point and 0.25 SSP point (a total of 0.5 point). Maximum 4 points possible (2 QPP and 2 SPP points). Creating and recording one HHP learning module earns 1 QPP point and 1 SSP point (a total
	of 2 points). Maximum 4 points possible (2 QPP and 2 SPP points).
Program	QPP & SSP
Inclusion	All eligible HHP members
Exclusion	N/A
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	Completion of HHP learning modules
	To create and record a learning module, contact Info@hawaiihealthpartners.org.
Eligible Members	All eligible HHP members
Proposed Learning Module Topics	Topics to be determined
How to Meet the Measure	Complete assigned HHP specific learning modules. If learning modules do not appear in assigned learning, providers should contact Info@hawaiihealthpartners.org.

ToDa	Completed	Destile	Catalan	Constant	tinte	D Talan Tala	
To Do	Completed	Profile ~	Catalog	Connections	Help	🔗 Take a Tour	1
Μν Τα	b-Do Lis	st					
OTAL TASKS							
UTAL MANA							
	1						
IOTAL TASKS	4						
		gned Learning 💽					
		gned Learning					
		gned Learning 🗲	1				
Show: All	Tasks 1 Assig		-	er	_		
Show: All	Tasks 1 Assi		-		ue: Dec 31,	2018	Start

QPP / SSP

QFF / 33F	
CITIZENSHIP	PARTICIPATION IN HHP CLINICAL WORKGROUPS
Measure Objective	Increase multi-specialty participation in HHP-chartered hospital or ambulatory clinical workgroups aimed at developing standards of care to improve quality, population health, care coordination, and cost of care
Description	Participation in HHP-chartered clinical workgroups See hawaiihealthpartners.org for more information on available workgroups and related responsibilities.
Points	Total possible points per workgroup: 1 - 4 points
	Workgroup Member Meaningful participation and attendance of at least 50% of meetings held earns 0.5 QPP point and 0.5 SSP point (a total of 1 point).
	Meaningful participation and attendance of at least 75% of meetings held earns 1 QPP point and 1 SSP point (a total of 2 points).
	Workgroup Chair Chairing a workgroup earns 2 QPP points and 2 SSP points (a total of 4 points).
Program	QPP & SSP
Inclusion	All eligible HHP members
Exclusion	N/A
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	Active participation in workgroups as reflected by attendance of at least 50% and demonstration of meaningful participation of workgroup member
Eligible Members	All eligible HHP members
How to Meet the Measure	Points earned will be determined by meaningful participation and contribution through attendance of at least 50% of meetings and through the demonstration of actual and verifiable work performed by workgroup members. Actual, verifiable work is defined as completing a workgroup task appropriate to the skills, education and/or training of a provider member that is documented in the minutes. Examples include researching and sharing evidence on appropriate use to the workgroup, presenting a case study to inform colleagues about a more efficient care delivery process/treatment method or leading a discussion with colleagues about reducing practice variation within the group. Attendance and meaningful participation must be performed by provider member and not by a staff proxy. Attendance and meaningful participation must be captured in meeting minutes, verified by workgroup chair, and then summarized in quarterly reporting to the Quality and Clinical Integration (QCI) Committee.
	continued on next page

ł

PARTICIPATION IN HHP CLINICAL WORKGROUPS

Workgroup Chair Job Description

Each workgroup chair is eligible to receive up to four points: two QPP points and two SSP points.

Each workgroup chair must be willing to assume the responsibility of ensuring a smoothly run and effective team.

The chair is expected to:

- 1. Ensure continued alignment of workgroup deliverables with shared savings and hospital quality performance interests.
- 2. Report workgroup status updates to the QCI Committee on a quarterly basis or more frequently as needed.
- 3. Develop specific expected outcomes and methods to track and measure progress.
- 4. Ensure adequate documentation of all workgroup related activities.
- 5. Ensure sustained engagement and participation of workgroup members.
- 6. Ensure workgroup produces stated deliverables in established timeline.
- 7. Include a plan for communicating any clinical process change or implementation.
- 8. Identify dependencies external to the workgroup and interact with the necessary departments or individuals to address the issue. (e.g., working with Epic project management to modify an Epic workflow).
- 9. Maintain a workgroup environment that welcomes all points of view, with a willingness to thoroughly discuss contentious or complex issues.
- 10. Encourage support for decisions made by majority rule.
- 11. Produce final document at the close of the workgroup summarizing work performed, results achieved, and lessons learned.

QUALITY PERFORMANCE

PROGRAM MEASURES

CARE DELIVERY

ADVANCE CARE PLANNING IN THE AMBULATORY SETTING

Measure Objective	Encourage advance care planning discussions and appropriate documentation for tracking such conversations, for HMSA attributed patients age 65 years and older
Description	Percentage of HMSA attributed patients who had an advance care plan and/or an advance care planning discussion documented in the patient record using standard coding (see below)
Points	1
Program	QPP
Numerator	Patients from the denominator who had an advance care plan and/or an advance care planning discussion, which is properly coded for in the patient's record
Denominator	HMSA attributed patients age 65 years or older
Exclusions	N/A
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	≥80%
	Primary Care: Individual score at or above 80% in Coreo or the HHP Dashboard
	Specialists: Overall HHP aggregate score at or above 80% in Coreo
Eligible Members	Primary Care: Internal Medicine, General Practice, Family Medicine, and APRNs carrying a primary care panel of attributed lives
	Specialists: Geriatric Medicine
How to Meet the Measure	Providers should use the following codes:
	CPT-II Codes:
	CPT 1157F – Advance care plan or similar legal document present in the medical record
	 CPT 1158F – Advance care plan discussion in the medical record CPT 1123F (Medicare) – Advance care planning discussed and documented; advance care
	plan or surrogate decision maker documented in the medical record
	 CPT 1124F – Advance care planning discussed and documented in the medical record; patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan
	continued on next page

ADVANCE CARE PLANNING IN THE AMBULATORY SETTING

CPT Codes:

- 99497 Advance care planning including the explanation and discussion of advance directives such as standard forms (with completion of such forms, when performed), by the physician or other qualified health care professional; first 30 minutes, face-to-face with the patient, family member(s), and/or surrogate
- 99498 Each additional 30 minutes (list separately in addition to code for primary procedure)

HCPCS Code:

 S0257 – Counseling and discussion regarding advance directives or end of life care planning and decisions, with patient and/or surrogate (list separately in addition to code for appropriate evaluation and management service)

Note: Epic will automatically update your ACP Health Maintenance (HM) Due when the codes listed above are used.

Note: This is an HMSA Payment Transformation related measure.

CARE DELIVERY

ADVANCE CARE PLANNING IN THE INPATIENT SETTING

Measure Objective	Encourage inpatient advance care planning (ACP) discussions and appropriate documentation for tracking such conversations, for patients age 65 years and older
Description	Assist patients with advance care planning during the inpatient stay—whether to initiate, confirm, or modify
Points	1
Program	QPP
Numerator	Patients who had an advance care plan and/or advance care planning discussion during an inpatient encounter, which is properly documented in the Problem List and properly coded (see below)
Denominator	N/A
Exclusions	N/A
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	≥15 completed and coded inpatient ACP discussions
Eligible Members	Critical Care Medicine, Hospitalist - Family Medicine, Hospitalist - Internal Medicine, Hospice and Palliative Medicine
w to Meet the Measure	1. Document the ACP discussion using this smartphrase: <i>.acphospitalcharge</i>
	2. Use the appropriate CPT code: 99497 (16 to 45 minutes) or 99498 (46+ minutes)

1	Abbrev	Expansion
4	ACPHOSPITALCHARGE	Advance Care Planning (ACP) Hospital Charge

I spent a total of *** minutes of face-to-face time devoted solely to providing Advanced Care Planning Services, which included counseling and discussion of goals of care. The patient/family said they would like a Code Status of ***. Additional decisions made about ACP include ***. Please refer to my notes for details. No active treatment took place during our Advance Care Planning discussion.

Hov

ENHANCED RECOVERY AFTER SURGERY (ERAS) ORDER SETS

Measure Objective	Promote the use of ERAS order sets for colorectal, gynecologic, hip fracture, and total joint surgical procedures
Description	Percentage of patients for whom an ERAS order set was completed pre-surgery, post-surgery, and intraoperatively
Points	Pre-surgical order set: 0.5 Point Post-surgical order set: 0.5 Point Intra-operative order set: 0.5 Point
Program	QPP
Numerator	Patients for whom an ERAS order set was used appropriately:
	 If discharged home post-surgery, patients for whom an ERAS order set was completed pre-surgery and intraoperatively
	 If admitted post-surgery, patients for whom an ERAS order set was completed pre-surgery, post-surgery, and intraoperatively
Denominator	Patients with an elective surgical procedure that falls into one of the following categories: colorectal, gynecology, hip fracture, total joint.
Exclusions	Ambulatory patients are excluded from the post-surgical ERAS order set measurement
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	 Pre-surgical order set: 25 order sets completed Post-surgical order set: 25 order sets completed Intra-operative order set: 25 order sets completed
Eligible Members	Anesthesiologists and surgeons (who perform colorectal, orthopedic, or gynecologic surgeries, including, but not limited to, the following specialties):
	- General Surgery - Gynecologic Oncology
	- Gynecology - Gynecology
	- Obstetrics & Gynecology
	- Orthopedic Surgery
	- Pediatric Surgery - Urogynecology & Pelvic Reconstruction
How to Meet the Measure	Complete the appropriate templated ERAS order set in Epic

HOSPITAL ACQUIRED HARM

Measure Objective		ians to continue efforts in elimina 1, Clostridium difficile, MRSA, hos ulcers							
Description	on the condition, which includ catheter days, recognition and	e rewards strategies to reduce hose e but are not limited to: reduction l early testing of patients at risk for ction with clinical staff regarding a k for harm.	n of central line or urinary or C. difficile identified at time						
Points		0 patient days in aggregate by f patient days in aggregate by fac	-						
Program	QPP								
Numerator	Total number of harm incident	S							
Denominator	Number of patient days	Number of patient days							
Exclusions	N/A								
Measurement Period	January 1, 2020 - December 31, 2020								
Performance Target	≤2 events / 10,000 patient day	Sevents / 10,000 patient days in aggregate by facility							
Case Threshold	5 hospital encounters								
Eligible Members	Facility based physicians:								
	 Anesthesiology Cardiac Electrophysiology Cardiology Critical Care Medicine Emergency Medicine Gastroenterology General Surgery Gynecologic Oncology Gynecology Hematology/Oncology Hospitalist - Family Medicine Hospitalist - Internal Medicine Hospitalist - Pediatrics Infectious Disease Interventional Radiology 	 Maternal & Fetal Medicine Neonatology Nephrology Neurology Neurosurgery Obstetrics & Gynecology Ophthalmology Orthopedic Surgery Otolaryngology Pediatric Cardiology Pediatric Critical Care Pediatric Emergency Medicine Pediatric Endocrinology Pediatric Gastroenterology Pediatric Hematology/ Oncology 	 Pediatric Infectious Diseases Pediatric Nephrology Pediatric Neurology Pediatric Pulmonology Pediatric Surgery Pediatric Urology Plastic Surgery Podiatry Pulmonology Surgical Oncology Thoracic Surgery Urogynecology & Pelvic Reconstruction Urology Vascular Surgery 						

OBSTRUCTIVE SLEEP APNEA SCREENING

Measure Objective	Reduce perioperative risk by increasing appropriate screening to detect undiagnosed obstructive sleep apnea in patients		
Description	Total number of patients aged 18 years or older who are screened for obstructive sleep apnea (OSA) by an anesthesiologist		
Points	1		
Program	QPP		
Numerator	Patients aged 18 years or older who are screened for obstructive sleep apnea by an anesthesiologist		
Denominator	N/A		
Exclusion	N/A		
Measurement Period	January 1, 2020 - December 31, 2020		
Performance Target	≥20 patients screened for OSA		
Eligible Members	Specialists: Anesthesiology		
How to Meet the Measure	Epic: The STOP-BANG* screener should be completed in Epic. It is available for documentation in the Preop Clinic nurses' navigator. The information documented will flow over to a view only section in the Anesthesiologist's navigator.		
	*STOP-BANG is an acronym which stands for Snoring, Tiredness, Observed apnea, blood Pressure, Body mass index, Age, Neck circumference, and Gender.		

QPP

ONCOLOGY STAGING: CLINICAL

Measure Objective	Improve effectiveness and efficiency of oncology care by consistent cancer staging			
Description	Intended to encourage the appropriate staging of oncologic disease uniformly across HPH via Epic's cancer staging tool			
Points	1			
Program	QPP			
Numerator	Number of newly diagnosed malignant cancer tumor cases clinically staged within Epic			
Denominator	Patients with stageable oncologic disease as determined by malignant pathological lab results			
Exclusion	N/A			
Measurement Period	January 1, 2020 - December 31, 2020			
Performance Target	≥60%			
Case Threshold	5			
Eligible Members	Applicable surgeons:			
	 Gastroenterology General Surgery Gynecologic Oncology Gynecology Hematology/Oncology Neurosurgery Obstetrics & Gynecology Ophthalmology 	 Orthopedic Surgery Otolaryngology Pediatric Gastroenterology Pediatric Hematology/ Oncology Pediatric Neurology Pediatric Surgery Pediatric Urology 	 Plastic Surgery Podiatry Surgical Oncology Thoracic Surgery Urogynecology & Pelvic Reconstruction Urology Vascular Surgery 	

continued on next page

ONCOLOGY STAGING: CLINICAL

How to Meet the Measure

Providers must complete the clinical oncology staging forms in Epic. They can be accessed directly from the problem list (see below).

The first three treating eligible surgeons are considered a member of the treatment team. If staging is completed by any of the three eligible surgeons, all will earn credit towards the measure.

Contact Oncology Service Line at oncologyserviceline@hawaiipacifichealth.org for more information.


4E @ \$1	Test.Obgm Uhp X	laskst 🎽 Chad 🚰 Hospital Chad #2 Patier	ni Lista 🔁 Form Réprinta 😧 Request Outside Records 🔛	- ZZSURGICAL - CSC - Productio Soluti Bowd (1) OR Schedule (1) C	21 Malatar OuchDedosure 💽 Stassour	a 🗶 Remind Ka	Promenta D'urs
	n Uhp Problem List	NUMBE AS SE COE	Allegges Holiston Adexong LOS Hot on File Name NUA Sdays				
of Review	Search for hew problem + Add	1					Iner Dest Pala
Alle Franke	Deplay. Management of Priority. Class: Oversites:	explain d left day () <u>Control of Accepto</u>) Need) Resolution () Resolution	Opene:				P
	Pier to gatory		Change Context 🔇 Po	ortol (El la Boai	vat 🎞 Obart 🖽	Happital Cha	rt ∳∃Patient Lists 🗐
						Hospital Cha	n TEPatient Lists
		Test, Obg	yn Uhp	MRN	Room/Bed	Age Sex	DOB Allergie Not on I
		← ← SnapShot Chart Review	Problem List	ote			
Maria e B	Ext. delivery care	Review Flows	Search for new problem	+ Add			
		Results Review	New Problem				
		Allergies	Problem:	Malignant neop	lasm of left ovary	(*)	
		History Problem List	Display:	Malignant neop	lasm of left ovary	(*)	
		-	Priority:		O Noted:	5/24/201	the second second
		Letters	Class: Overview: ☆ B ⊕ ॐ	🖍 🕄 🕇 (ns	Resolved:	~ ~ ~ ~ ~	

Step 1


continued on next page

ONCOLOGY STAGING: CLINICAL

Step 2







PERIOPERATIVE SURGICAL HOME: SURGEON PARTICIPATION

Measure Objective	Improve surgical outcomes by assuring appropriate preoperative optimization for elective surgery		
Description	Percentage of elective surgical patients with preoperative surgical screening checklist completed within Epic		
Points	1		
Program	QPP		
Numerator	Patients with an appropriate preoperative surgical screening checklist completed in Epic		
Denominator	Patients with an elective surgical procedure		
Exclusions	Inpatient and emergent surgical procedures		
Measurement Period	January 1, 2020 - December 31, 2020		
Performance Target	≥60%		
Case Threshold	20		
Eligible Members	Applicable surgeons:		
	 General Surgery Gynecologic Oncology Gynecology Neurosurgery Obstetrics & Gynecology Ophthalmology 	 Orthopedic Surgery Otolaryngology Pediatric Surgery Pediatric Urology Plastic Surgery Podiatry 	 Surgical Oncology Thoracic Surgery Urogynecology & Pelvic Reconstruction Urology Vascular Surgery
How to Meet the Measure	Providers should complete the preoperative surgical screening checklist in Epic.		
	Step 1.		
	Type SmartPhrase: .readyforsurgery or .readyforsurgerypeds		
	Step 2.		
	Answer all screening questions in the presurgical risk screening tool built in Epic.		
	• If all responses are 'no,' the patient may be scheduled for surgery.		
	 If any one answer is 'yes,' the patient needs anesthesia clearance before surgery. Please schedule a preanesthesia visit and assist the patient to obtain indicated testing and/or necessary evaluation by their PCP, cardiologist, pulmonologist, etc. prior to the PACT visit. 		
	Contact Info@hawaiihealthpartners.org for more information.		

SEPSIS AND SEPTIC SHOCK: MANAGEMENT BUNDLE (COMPOSITE MEASURE)

Measure Objective	Support comprehensive care of sepsis and septic shock		
Description	Cumulative monthly sepsis and septic shock core measure result (%) This measure will focus on patients aged 18 years and older who present with symptoms of sepsis or septic shock. These patients will be eligible for the 3 hour (sepsis) and/or 6 hour (septic shock) early management bundle (ref: CMS measure: SEP-1).		
Points	Critical Care Medicine, Emergency Medicine, Hospitalist - Family Medicine, Hospitalist - Internal Medicine, and Hospitalist - Pediatrics eligible to earn:		
	≥70% = 1 point ≥80% = 2 points		
	Applicable surgeons eligible to earn: ≥70% = 0.5 point ≥80% = 1 point		
Program	QPP		
Numerator	Patients from the denominator who received all the following care elements (see A, B, and C below) within 3 hours of time of presentation.		
	IF septic shock is present (defined by hypotension or lactate >=4 mmol/L), patients from the denominator who also received additional care elements (see D, E, F, and G below) within 6 hours of time of presentation.		
	A. Measure lactate level		
	B. Obtain blood cultures prior to antibiotics		
	C. Administer broad spectrum antibiotics		
	D. Administer 30 ml/kg crystalloid for hypotension or lactate = 4 mmol/L		
	E. Apply vasopressors (for hypotension that does not respond to initial fluid resuscitation to maintain a mean arterial pressure = 65)		
	F. In the event of persistent hypotension after initial fluid administration (MAP <65 mmHg) or if initial lactate was = 4 mmol/L, re-assess volume status and tissue perfusion and document findings.		
	To meet the requirements, a focused exam by a licensed independent practitioner (LIP) or any 2 other items are required:		
	Measure CVP		
	Measure ScvO2		
	Bedside cardiovascular ultrasound		
	• Dynamic assessment of fluid responsiveness with passive leg raise or fluid challenge		
	 Focused exam including vital signs, cardiopulmonary, capillary refill, pulse, and skin findings 		
	G. Remeasure lactate if initial lactate is elevated		

Denominator	All patients presenting with sepsis or septic shock and discharged with a diagnosis of sepsis or septic shock (the cohort is defined by discharge coding)					
Exclusion	A) Patients with advanced directives for comfort care					
	B) Clinical conditions that preclude total measure completion (e.g. mortality within the first 6 hours of presentation)					
	C) Patients for whom a central line is clinically contraindicated (e.g. coagulopathy that cannot be corrected, inadequate internal jugular or subclavian central venous access due to repeated cannulations)					
	D) Patients for whom a centra	D) Patients for whom a central line was attempted but could not be successfully inserted				
	E) Patient or surrogate decision maker declined or is unwilling to consent to such therapies or central line placement					
	F) Patients transferred to an ad	F) Patients transferred to an acute care facility from another acute care facility				
Measurement Period	January 1, 2020 - December 31, 2020					
Performance Target	To be scored in aggregate by facility					
	≥80%					
Eligible Members	Critical Care Medicine, Emergency Medicine, Hospitalist - Family Medicine, Hospitalist - Internal Medicine, Hospitalist - Pediatrics, and applicable surgeons:					
	General Surgery	Orthopedic Surgery	Surgical Oncology			
	 Gynecologic Oncology 	 Otolaryngology 	Thoracic Surgery			
	 Gynecology 	Pediatric Surgery	 Urogynecology & Pelvic 			
	Neurosurgery	Pediatric Urology	Reconstruction			
	Obstetrics & Gynecology	Plastic Surgery	• Urology			
	 Ophthalmology 	 Podiatry 	 Vascular Surgery 			

CARE DELIVERY

VERMONT OXFORD NETWORK FOR VLBW AND EXPANDED DATABASE MEASURES

Measure Objective	Encourage optimal clinical management of premature newborns			
Description	The amount of points earned by an eligible provider under the Vermont Oxford Network (VON) measures for very low birth weight (VLBW) and expanded database patients			
	VLBW - Incidence of necrotizing enterocolitis			
	VLBW - Nosocomial infection			
	VLBW - Any human milk at discharge to home			
	VLBW - Death or Morbidity			
	VLBW - Oxygen at 36 weeks			
	Expanded - Nosocomial infection			
	Expanded - Any human milk as discharge to home			
	Expanded - Mortality Excluding Early Deaths			
Points	Maximum 2.5			
	8 measures x 0.3125 points/measure			
Program	QPP			
Numerator	Patients who meet each individual VON metric criteria			
Denominator	All patients admitted to the NICU at Kapi'olani Medical Center for Women & Children (KMCWC)			
	Expanded definition: All NICU admissions			
	VLBW definition: All very low birth weight NICU admissions (a subset of the expanded dataset)			
Exclusion	Admitted from home after being hospitalized			
	Admitted ≥28 days of life			
Measurement Period	January 1, 2020 - December 31, 2020			
Performance Target	Top quartile = 0.3125 points for each measure x 8			
Eligible Members	Neonatologists and Pediatricians practicing as NICU Hospitalists who are members of the Kapi'olani Medical Specialists Division of Neonatology			

Creating a heathier Hawai'i

SHARED SAVINGS PROGRAM MEASURES

SSP

CARE DELIVERY

ADOLESCENT HPV IMMUNIZATION

Measure Objective	Prevent cancers caused by Human Papillomavirus (HPV), especially cervical and oropharyngeal cancers, by immunizing for HPV in adolescents
Description	Percentage of attributed adolescent patients who received the HPV vaccine on or before the patient's 13th birthday
Points	Total possible: 2 points HMSA Commercial: 1 point HMSA Quest: 1 point
Program	SSP
Numerator	Patients from the denominator with at least two HPV vaccines with different service dates on or before the patient's 13th birthday. The first and second doses must be administered at least 146 days apart OR at least three HPV vaccines with different dates of service on or before the patient's 13th birthday.
Denominator	Adolescent HMSA patients who turn 13 years of age during the measurement period
Exclusions	Adolescents who have a contraindication for one of these vaccines (exclusion must have occurred before the adolescent's 13th birthday)
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	≥60%
Eligible Members	Primary Care: Pediatrics, Family Medicine, and APRNs carrying a primary care panel of attributed lives with ≥40 HMSA attributed patients who turn 13 years of age during the measurement period
How to Meet the Measure	In office (Epic & non-Epic): Providers should use the appropriate immunization procedure code: 90649, 90650, 90651. For updated codes: hmsa.com/portal/provider/zav_pel.aa.PAY.100.htm Outside immunizations (Epic): Providers must complete Historical Immunizations in Epic for outside immunizations (see next page). Outside immunizations (non-Epic): Providers must make all updates in Coreo (see next page).
	continued on next page

Outside Immunizations (Epic)

SnapShot	Historical Immunizations Template to use: COMPLETE ALP			
Chart Review			10-20	
Care Everywh	Immunization	DATE	DATE	DATE
Results Revi	30 HPV2 [555118]			
	31 HPV4 [55973]			1
Review Flows	32 HPV9 [555165]	10/11/2018	6/12/2018	1/23/2018
Problem List	33 INFLUENZA VACC SPLIT VIRUS NO	PRESERVATIVES [90	£	1
History	34 Influenza Vacc Split Virus, No presen	vatives [559003]		
	35 Influenza Vacc Split Virus, No preserv	atives, 6-35 Mos (9003		
Letters	36 Influenza Vacc, Split [9002]			
Demographics	37 Influenza Vacc, Split, 6-35 mos [9001	1		
Immunizations	38 Influenza Virus Vaccine - Split High D	ose [552802]		
Allereise	39 Influenza Virus Vaccine - Whole [28]			
Allergies	40 Influenza Virus Vaccine - Whole [280	02]		
Medications	41 Influenza Virus Vaccine - Whole Flu S	Shot Clinic [552800]		
Growth Chart	42 Influenza Virus Vaccine - Whole, Intra	inasal [28001]		
Health Mainte	43 Influenza Virus Vaccine Split [9]			1
ricalar mainte	44 Influenza Virus Vaccine, Intranasal (flu	u Mist) [55354]		
DDA Davisiu	45 INFLUENZA VIRUS VACCINE, UNLIS	STED VACCINES AND		
BPAReview	46 Influenza, High-dose Seasonal, Prese	rvative Free [555135]		
Synopsis	47 Influenza, Injectable, Quadrivalent [55	5158]		
Enter/Edit Re	48 Influenza, Injectable, Quadrivalent, Pre	eservative Free [555150 10/11/2018		
	49 Influenza, Injectable, Quadrivalent, Pre	servative Free, Pediatri		
	50 IPV [13]	2/13/2007	8/3/2004	8/6/2003
	51 Japanese Encephalitis, Intramuscular	[55100001]		-
	52 Japanese Encephalitis, Subcutaneous	s [55100]		
	53 Japanese Encephalitis, Subcutaneous	s [55100002]	1	1
	54 Measles [10]			
	55 Measles/Rubella [30]			
	56 Meningococcal (menactra/menveo) [9	95841 2/1/2014		

Coreo Immunization Documentation

HPV Vaccine Dose 1 Procedure Date mm/dd/yyyy	Procedure	Modifier	
Place of Service	Performed By	Result	
HPV Vaccine Dose 2 Procedure Date	Procedure	Modifier	
mm/dd/yyyy Place of Service	Performed By	Result	

Measure Objective	Improve immunization rates in adolescents
Description	Percentage of adolescents 13 years of age who had one dose of meningococcal vaccine and one tetanus, diphtheria, and acellular pertussis vaccine (Tdap) by their 13th birthday
Points	Total possible: 2 points HMSA Commercial: 1 point HMSA Quest: 1 point
Program	SSP
Numerator	Adolescents who receive both: One meningococcal conjugate vaccine on or between their seventh and 13th birthdays, and one Tdap on or between their seventh and 13th birthdays
Denominator	Adolescents who turn 13 years of age during the measurement period
Exclusions	Adolescents who have a contraindication for one of these vaccines Exclusion must have occurred before the adolescent's 13th birthday
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	≥85%
Eligible Members	Primary Care: Pediatrics, Family Medicine, and APRNs carrying a primary care panel of attributed lives with ≥40 HMSA attributed patients who turn 13 years of age during the measurement period
How to Meet the Measure	In office (Epic & non-Epic): Providers should use the appropriate immunization procedure code: 90733, 90734, 90644, 108, 114, 136, 147, 148, 90715, 115. For updated codes: hmsa.com/portal/provider/zav_pel.aa.PAY.100.htm Outside immunizations (Epic): Providers must complete Historical Immunizations in Epic for outside immunizations (see next page). Outside immunizations (non-Epic): Providers must make all updates in Coreo (see next page). <i>continued on next page</i>

Outside Immunizations (Epic)

apShot	- Historical Immunizations				
art Review	Template to use: COMPLETE ALPHABETIZED IMMUNIZAT				
	Immunization	DATE	DATE	DATE	
are Everywh	56 Meningococcal (menactra/menveo) [99584]	2/1/2014	UAIL	DAIL	
esults Revi	57 Meningococcal (menomune) [99583]	2/1/2014		1	
eview Flows	58 Meningococcal B, OMV (Bexsero) [55163]	-	-	-	
	59 Meningococcal B, Recombinant (Trumenba) [55162]	-	-	-	
oblem List	60 Meningococcal C, Conjugate [555103]	_	-	-	
istory		_		-	
tters	61 Meningococcal Vaccine [31]	1/29/2004		-	
mographics	62 MMR [11]	1/25/2004	-	1	
emographics	63 Mumps [4]	_		-	
munizations	64 Mumpsvax [32]	_	-		
lergies	65 OPV [12]	_		-	
disabless	66 PEDIARIX (Dtap-IPV-HepB) [55026]	_	-	-	
edications	67 Pentacel (Dtap-IPV-HIB) [55092501]				
rowth Chart	68 Pneumococcal PCV13 (Prevnar13) [55101]	_	_	-	
ealth Mainte	69 Pneumococcal PCV7 (Prevnar) [55102]	-	tooler	here	
	70 Pneumococcal Vaccine, Conjugate - Historical [14]	8/6/2003	5/8/2003	2/12/2003	
PAReview	71 Pneumococcal PPSV23 (Pneumovax 23) [33]			1	
A CONTRACTOR OF THE OWNER OF THE	72 Proquad (MMR-V) [55401]	2/13/2007			
ynopsis	73 PURIFIED PROTEIN DERIVATIVE (PPD) [34]	7/31/2007			
nter/Edit Re	74 Rabies Immune Globulin [35]				
	75 Rabies Vaccine [36]			1	
	76 Rabies Vaccine, Intradermal [36001]			-	
	77 Rabies Vaccine, IM Fibroblast [555176]			-	
	78 Rabies Vaccine, IM - Historical [36002]		-	1	
	79 Recombivax HB (11-19 Yrs) [37]	_		-	
	80 Recombivax Hb (Newborn-10 Yrs) [38]	-		-	
	81 Rhogam (IP) [55371]			-	
	82 Rotarix [57]			-	
	83 Rotashield [55959]	-			
	84 Rotateg [55960]		-	1	
	85 Rotavirus [39]			-	
	86 Rubella (German Measles) [5]				
	87 Rubella/Mumps [40]	-			
	88 Smallpox [55027]				
	89 Synagis [55999]		1		
	90 Tdap [55350]	2/1/2014			
	91 Tetanus Immune Globulin, Human [42]				
	92 Tetanus Toxoid, Absorbed [1]				
	93 Tetanus/Diphtheria [41]				
	94 Tetanus/Diphtheria [43]				
	95 Tetanus/Diphtheria, 7 yrs and older [41002]				
	96 Tetanus/Diphtheria, No Preservatives, 7 Yrs and Older [41	00			
	97 TriHIBit (DTaP-Hib) [44]				
	98 Twinrix [65301]				
	99 Typhoid [15]				
	100 Typhoid H-P [15001]				
	101 Typhoid VICPS [15002]				
	102 Varicella Vaccine [16]	1/29/2004			
	103 Varicella-Zoster IG [45]		1	-	
	104 Varicella-Zoster, Intramuscular [55971002]				
	105 Varigrip [58]				
	106 Yellow Fever, Live [46]				
	107 Zostavax DO NOT USE [55971]				

continued on next page

Coreo Immunization Documentation

nmunizations for Adolese	ents		
ease Indicate the services for wh	ch you have on record as recei	ved by the patient and date of the service.	
Meningococcal			
Procedure Date	Procedure	Modifier	
mm/dd/yyyy			*
Place of Service	Performed By	Result	
	•	P	
Tdap		1	
Procedure Date	Procedure	Modifier	
Procedure Date			

ADOLESCENT WELL-CARE VISIT

Measure Objective	Improve the care of adolescents
Description	Percentage of patients 12 up to 17 years of age who had at least one comprehensive well-care visit with an eligible PCP during the measurement period
Points	Total possible: 2 points
	HMSA Commercial: 1 pointHMSA Quest: 1 point
Program	SSP
Numerator	Patients with at least one well-care visit with an eligible PCP* during the measurement period
	*The visit does not need to be completed by the patient's attributed PCP
Denominator	HMSA attributed patients 12 up to 17 years of age at the end of the measurement period
Exclusions	None
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	≥55%
	Individual score at or above 55% in either Coreo or HHP dashboard
Eligible Members	Primary Care: Pediatrics, Family Medicine, General Practice, and APRNs carrying a primary care panel of attributed lives with ≥100 HMSA attributed patients ages 12 up to 17 years of age at the end of the measurement period
How to Meet the Measure	Providers should use the appropriate HMSA Payment Transformation well-care visit codes: hmsa.com/portal/provider/zav_pel.aa.PAY.100.htm
	Note: This is an HMSA Payment Transformation related measure.

AVOIDABLE ED UTILIZATION

Masaura Ohiaatiua	
Measure Objective	Encourage patients to first seek care in the most appropriate care setting
Description	Percentage of ED visits by HMSA Commercial attributed patients that are "avoidable" according to adapted NYU criteria
Points	1
Program	SSP
Numerator	Patient ED visits from the denominator that are "avoidable" according to adapted NYU criteria
Denominator	HMSA Commercial attributed patients that present to an ED
Exclusion	N/A
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	Primary Care: Individual performance scored at or below 15% in HHP Dashboard
	Specialists: Overall HHP aggregate score at or below 15%
Eligible Members	Primary Care: Internal Medicine, General Practice, Family Medicine, Pediatrics, and APRNs carrying a primary care panel of attributed lives with ≥400 attributed patients at the end of the measurement period
	Specialists: Specialties engaging in face-to-face patient care Excludes Diagnostic Radiology, Medical Genetics, Neuroradiology, Nuclear Medicine, and Pathology
How to <i>Monitor</i> the Measure	Primary Care Providers should monitor avoidable ED visits on the HHP Dashboard in Epic to identify appropriate interventions (see below).
	Hawai'i Health Partners Primary Care Dashboard
	HAWAI'I HAWAI'I Physician Panel Composition Access All Poyors All Poyors All Poyors HMSA & All Poyors All Poyo
	PCP NAME Clinic Last refresh as of 10/15/2019 Data refreshed monthly
	Adjusted Panel Size O Same Day Appts O Patient Service O Physician Name
	🕅 1,900 🕥 21% 🔓 2 of 5
	As of Sep 2019 As of Sep 2019 As of Dec 2018 - Mar 2019

Total Cost of Care

1%

jan-Dec 2018 vs jan-Jul 2019

dable ED %

Jan 2019 - Jul 2019

29%

3

tory Quality

26 of 34

As of 10/7/2019

CARE DELIVERY

AVOIDABLE ED UTILIZATION

Each ED visit is considered "avoidable" as determined by the likelihood that an individual ED visit was "avoidable" according to NYU's Avoidable ED algorithm. This is determined for attributed lives for each PCP (attribution is based on the HMSA eligibility file). Both the primary and secondary diagnoses will be evaluated to determine if the visit was avoidable. A visit is considered avoidable if the likelihood of that visit according to the adapted NYU Avoidable ED algorithm falls into the first three of the following four categories:

1. Non-Emergent (ED level 1):

The patient's initial complaint, presenting symptoms, vital signs, medical history, and age indicated that immediate medical care was not required within 12 hours.

2. Emergent/Primary Care Treatable (ED level 2):

Based on information in the record, treatment was required within 12 hours, but care could have been provided effectively and safely in a primary care setting. The complaint did not require continuous observation, and no procedures were performed or resources used that are not available in a primary care setting (e.g., CAT scan or certain lab tests).


3. Emergent - ED Care Needed - Preventable/Avoidable (ED level 3):

Emergency department care was required based on the complaint or procedures performed/resources used, but the emergent nature of the condition was potentially preventable/avoidable if timely and effective ambulatory care had been received during the episode of illness (e.g., the flare-ups of asthma, diabetes, congestive heart failure, etc.)

4. Emergent - ED Care Needed - Not Preventable/Avoidable (ED level 4):

Emergency department care was required and ambulatory care treatment could not have prevented the condition (e.g. trauma, appendicitis, myocardial infarction, etc.).

Specifications and background for the NYU Avoidable ED Visit algorithm are available at: wagner.nyu.edu/faculty/billings/nyued-background



SSP

CARE DELIVERY

CONTROLLING HIGH BLOOD PRESSURE

Measure Objective	Avoid morbidity associated with uncontrolled hypertension by supporting active monitoring and management of hypertension in patients
Description	HMSA Commercial, Akamai, Quest, and Essential Advantage attributed patients 18 through 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled during the measurement period
Points	Total possible: 1.5 points
	 HMSA Commercial: 0.5 point HMSA Akamai and Essential Advantage: 0.5 point HMSA Quest: 0.5 point
Program	SSP
Numerator	Patients whose blood pressure at the most recent visit in a primary care setting is adequately controlled (<140/90 mm Hg) during the measurement period
Denominator	HMSA Commercial, Akamai, Quest, and Essential Advantage attributed patients 18 through 85 years of age who had a diagnosis of hypertension during the measurement year or the year before the measurement year
Exclusion	• Patients with evidence of end stage renal disease (ESRD), dialysis, or renal transplant before or during the measurement period
	 Patients with a diagnosis of pregnancy during the measurement period
	Patients who were in hospice care during the measurement period
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	Performance by line of business:
	 HMSA Commercial: ≥85%
	HMSA Akamai and Essential Advantage: ≥85%
	 HMSA Quest: ≥85%
	Primary Care: Individual score at or above 85% in Coreo or the HHP Dashboard
	Specialists: Overall HHP aggregate score at or above 85% in Coreo
Eligible Members	Primary Care: Internal Medicine, General Practice, Family Medicine, and APRNs carrying a primary care panel of attributed lives
	Specialists: Cardiology, Nephrology, Endocrinology
	continued on port page

continued on next page

CONTROLLING HIGH BLOOD PRESSURE

How to Meet the Measure

Epic: Providers must document blood pressure in the Vital Signs section in Epic (see below).

Non-Epic: Providers must document blood pressure in Coreo (see next page for two ways to document).

Note: This is an HMSA Payment Transformation related measure.

Epic Vital Signs section

***	Rooming	00	2
SnapShot	Screening Chief Complaint Wital Signs Smoking Assessment Care Everywhere Review Allergies Verify Rx Benefits Outside Meds Home Medications History Immun. Rpt		
Chart Review Care Everywh	Vital Signs 10/2/18 8:24 AM New Set of Vitals Taken on 10/2/18 8:24 AM C Othostatics Exclude from Growth Charts	11	1
Rooming History Screens/Flow	BP: Weight: 28 lb (12.701 kg) Pain score: 0-No pain Pain score: Site: Position: Pite Height: 3' 1" (0.94 m) Location: Pite Position: Pite HC: 20" (50.8 cm) Comment: Pite Pulse: SpO2: Proport Comment: Pite Source: Temporal Scan P		
Nursing Note Notes	Terrevious I	Next	
Plan	I Smoking Assessment ≠ I New Reading Flore	O wsheets p	

continued on next page

Coreo Blood Pressure Documentation

Option 1:

nd Diastolic values. If you cannot us	patient and the date of the service.	
section of this form to report the m		pressu
Procedure	Modifier	
	•	
Performed By	Result	
-		
Procedure	Modifier	
Performed By	Result	1.
	Performed By Procedure	Performed By Procedure Modifier

Option 2:

Date mm/dd/yyyy	Time			
Temperature	Pulse bpm	Blood Pressure	Respiration rpm	Oxygen SP02
Height In	Weight Ibs.			

DIABETES BUNDLE - PRIMARY CARE

Measure Objective	Reduce morbidity associated with diabetes by encouraging glycemic control and the identification and timely management of both diabetic retinopathy and nephropathy
Description	Percentage of HMSA Commercial, Akamai, Quest, and Essential Advantage attributed patients 18 to 75 years of age with diabetes who are compliant with each of the following three care goals: • Diabetes: Eye exam
	Diabetes: Hemoglobin A1c controlDiabetes: Nephropathy screening
Points	If 50% of the HMSA attributed diabetic patients meet all three care goals (A1c, eye exam, and nephropathy screening), then points are awarded.
	Total possible: 9 points
	HMSA Commercial: 3 pointsHMSA Akamai and Essential Advantage: 3 points
	HMSA Quest: 3 points
Program	SSP
Numerator	Patients from the denominator who are compliant with ALL the following care goals during the measurement period:
	1. Diabetes: Eye Exam
	Patients who had one of the following eye screenings for diabetic retinal disease:
	 A retinal or dilated eye exam by an eye care professional in the measurement period
	or
	 A negative retinal or dilated exam (no evidence of retinopathy) by an eye care professional in the year prior to the measurement period
	2. Diabetes: Hemoglobin A1c Control
	Patients whose most recent HbA1c level (performed during the measurement period) is \leq 9.0%
	3. Diabetes: Nephropathy Screening
	Patients who had one of the following:
	 Screening for nephropathy
	Evidence of nephropathy
	 Evidence of ACE inhibitor/ARB therapy (from pharmacy claims)
	Evidence of stage 4 chronic kidney disease
	Evidence of ESRD
	Evidence of kidney transplant
	• A visit with a nephrologist, as identified by the organization's specialty provider codes
	Billing codes from claims will also be used to identify screening for nephropathy and evidence of nephropathy: hmsa.com/portal/provider/zav_pel.aa.PAY.100.htm

DIABETES BUNDLE - PRIMARY CARE

Denominator	HMSA Commercial, Akamai, Quest, and Essential Advantage attributed patients 18 to 75 years of age with diabetes					
Exclusions	Patients who were in hospice care during the measurement period					
Measurement Period	January 1, 2020 - December 31, 2020					
Performance Target	≥50% of individual diabetic patients who are compliant with all 3 measures in either Coreo or HHP Dashboard by line of business					
	 Performance by line of business: HMSA Commercial: ≥50% HMSA Akamai and Essential Advantage: ≥50% HMSA Quest: ≥50% 					
Eligible Members	Primary Care: Internal Medicine, General Practice, Family Medicine, and APRNs carrying a primary care panel of attributed lives					
How to Meet the Measure: Eye Exam	Diabetes: Eye Exam In Office (Epic & non-Epic): Providers performing eye exam should use the appropriate 2020 HMSA Payment Transformation codes when applicable: hmsa.com/portal/provider/ zav_pel.aa.PAY.100.htm Outside Exams (Epic): Providers must document external eye exams in the quality metrics results console (see below). Outside Exams (non-Epic): Providers must document in Coreo (see next page). Epic Quality Metrics Results Console					
	Quality Metrics Results Console Image: Console Image: Result Console Image: Console Result Defaults: Image: Console Defaults: Image: Console Show: Result Time: Operation					
	Leb: Leb:					
	Vríne Atbumin					

continued on next page

Coreo Eye Exam Documentation

iabetes Care – Eye Exam			
		ne patient and the date of the service. If the patient	hac
ye exam, include the name of the e	eye care professional that completed t	he exam.	
Dilated Eye Exam			
Procedure Date	Procedure	Modifier	
mm/dd/yyyy			
Place of Service	Performed By	Result	
	•	P	
Negative Retinal Eye Exa	m		
Procedure Date	Procedure	Modifier	
and the first of the second se		1	1
mm/dd/yyyy			

How to Meet the Measure: HbA1c Control

Diabetes: Hemoglobin A1c Control

Epic: Providers must document external labs in Epic using the quality results console (see below).

Non-Epic: Providers must document in Coreo (see next page).

Epic Quality Metrics Results Console

Results Console				
Result Date:	Result Time		0	Show: Ret. Range
Provider:	2	Lab:	0	new. Liver nange
Internal Women's Health		U-	External Colorectal Cancer Screening	
M Pap Test		V	J Colonoscopy	
M Chlamydia Scree		U	Flexible Sigmoido	
M HPV Test		N	Fecal Occult Bloo	
liternal Diabetes Screening	js	U-	External Women's Health	
V Diabetic Eye Exam		V	Ø Pap Test	
		U	Chlamydia Scree	
		U		
		U	J Mammogram	
		10-	External Diabetes Screenings	
		W	Diabetic Foot Exam	
		8	Diabetic Eye Exam	
		He	emoglobin A1c 🧧 % 🗅	6 0
		le)	Urine Albumin	
		10-	+ External Cardiac Screenings	
		W	J Total Cholesterol	
			ປີ Total Cholesterol ປີ LDL	

Coreo HbA1c Documentation

2022			
Diabetes Care – HbA1c	In Control (<=9.0)		
shows a state of the share of the state of the	CONTRACTOR AND AND AND ADDRESS OF A DATABASE AND ADDRESS	e patient and the date of the service. Select a proce	dura .
or LOINC code to indicate the n	nember received an HbA1c test and report th		oure
	nember received an HbA1c test and report th		-

How to Meet the Measure: Nephropathy Screening

Diabetes: Nephropathy screening

Non-Epic: Providers must document in Coreo (see below).

Coreo Nephropathy Documentation

2022			
)iabetes Care – Medical	Attention for Nephropathy		
Nephropathy screeni	ng/ monitoring test		
Procedure Date	Procedure	Modifier	_
mm/dd/yyyy	-		
Place of Service	Performed By	Result	
Place of Service			

DIABETES: EYE EXAM - SPECIALISTS

Measure Objective	Support the identification and timely management of diabetic retinopathy in patients with diabetes
Description	Percentage of HMSA Commercial, Akamai, Quest, and Essential Advantage attributed patients 18 to 75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal or dilated eye exam (no evidence of retinopathy) in the 12 months prior to the measurement period
Points	Total possible: 1.5 points • HMSA Commercial: 0.5 point • HMSA Akamai and Essential Advantage: 0.5 point • HMSA Quest: 0.5 point
Program	SSP
Numerator	 Patients with an eye screening for diabetic retinal disease This includes diabetics who had one of the following: A retinal or dilated eye exam by an eye care professional in the measurement period or A negative retinal or dilated exam (no evidence of retinopathy) by an eye care professional in the year prior to the measurement period
Denominator	HMSA Commercial, Akamai, Quest, and Essential Advantage attributed patients 18 to 75 years of age with diabetes
Exclusion	Patients who were in hospice care during the measurement period
Measurement Period	January 1, 2020 - December 31, 2020 (once per reporting period)
Performance Target	 Performance by line of business: HMSA Commercial: ≥80% HMSA Akamai and Essential Advantage: ≥80% HMSA Quest: ≥80% Specialists: Overall HHP aggregate score at or above 80% in Coreo by line of business
Eligible Members	Specialists: Endocrinology, Ophthalmology
	continued on next page

DIABETES: EYE EXAM - SPECIALISTS

How to Meet the Measure

Collaborate with Primary Care Providers on diabetic eye care management.

Epic & non-Epic: Providers performing eye exam should use the appropriate 2020 HMSA Payment Transformation codes when applicable: hmsa.com/portal/provider/ zav_pel.aa.PAY.100.htm

Epic: Providers must follow proper procedures for documenting external eye exams in the quality metrics results console (see below).

Note: This is an HMSA Payment Transformation related measure.

Epic Quality Metrics Results Console

etrics Results Co	nsole				000
Console Result Date:	a	Result Time:	Ø	Provider:	5 Show: Rel. Ranges
al Diabetes Screenings tic Eye Exam					External Colorectal Cancer Screening Colonoscopy Ø Colonoscopy Plexible Sigmoldoscopy Ø Flexible Sigmoldoscopy Plexible Sigmoldoscopy
					상+ External Diabetes Screenings V Diabetic Foot Exam Diabetic Eye Exam Negative 오 고 (2011년 전) 이 (2011년 전) 이 (2011년 전) 이 (2011년 전) 이 (2011년 전)
	Console Result Date: Lab:	Result Date: 🖄 Lab: 🔤	Console Result Date: C Result Time: Lab: P D Il Diabetes Screenings	Console Result Date: 2 Result Time: 0 Lab: 2 D	Console Result Date: C Result Timè: O Provider: C Leo: D al Diabates Screenings Sic Éye Exam

DIABETES: HEMOGLOBIN A1C (HBA1C) CONTROL - SPECIALISTS

Measure Objective	Reduce morbidity associated with diabetes by supporting glycemic control
Description	Percentage of HMSA Commercial, Akamai, Quest, and Essential Advantage attributed patients 18 to 75 years of age with diabetes who had hemoglobin A1c ≤9.0% during the measurement period
Points	Total possible: 3 points • HMSA Commercial: 1 point • HMSA Akamai and Essential Advantage: 1 point • HMSA Quest: 1 point Total: 3 points
Program	SSP
Numerator	Patients from the denominator whose most recent HbA1c level (performed during the measurement period) is \leq 9.0%
Denominator	HMSA Commercial, Akamai, Quest, and Essential Advantage attributed patients 18 to 75 years of age with diabetes
Exclusion	Patients who were in hospice care during the measurement period
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	 Performance by line of business: HMSA Commercial: ≥85% HMSA Akamai and Essential Advantage: ≥85% HMSA Quest: ≥85% Specialists: Overall HHP aggregate score at or above 85% in Coreo by line of business
Eligible Members	Specialists: Endocrinology
	continued on next page

How to Meet the Measure

Collaborate with Primary Care Providers on diabetic care management.

Epic: Providers must follow proper procedures for documenting external labs in the quality metrics results console (see below).

Note: This is an HMSA Payment Transformation related measure.

Epic Quality Metrics Results Console

Results Console	
Defaults: Result Date: Result Time: Lab:	Show: Ret. Ranges
M+ Internal Women's Health	U+ External Colorectal Cancer Screening
Now V Pap Test	M Colonoscopy
V Chlamydia Scree	V Flexible Sigmoido
M HPV Test	V Fecal Occult Bloo
lote ↓ Internal Diabetes Screenings	lij-→ External Women's Health
V Diabetic Eye Exam	U Pap Test
	U Chlamydia Scree
	U HPV Test
	Mammogram
	14 External Diabetes Screenings
	V Diabetic Foot Exam
	U Diabetic Eye Exam
	Hemoglobin A1c 🚺 % 🗅 👘 📀
icati	Urine Albumin
	U+ External Cardiac Screenings
Duts	U Total Cholesterol
etno	V LDL
	M HDL

DIABETES: HEMOGLOBIN A1C (HBA1C) LAB COMPLETION RATE

Measure Objective	Reduce morbidity associated with diabetes by supporting measurement of glycemic control
Description	Percentage of diabetic patients who have completed at least one HbA1c lab during the measurement year
Points	2
Program	SSP
Numerator	Patients from the denominator who had at least one HbA1c lab completed during the measurement year
Denominator	HMSA Commercial, Akamai, Quest, and Essential Advantage attributed patients 18 to 75 years of age with diabetes attributed to the clinic* on December 31, 2020
	*Note: If a PCP leaves a clinic, their patients will remain attributed to the clinic until attributed to another PCP.
Exclusion	Patients who were in hospice care during the measurement period
Measurement Period	January 1, 2020 - December 31, 2020
Clinic Size Threshold	Clinics with ≥100 attributed diabetic patients
Performance Target	≥88% = 0.5 point ≥90% = 1 point ≥92% = 2 Point Primary Care: Aggregate clinic score at or above 92%
Eligible Members	Primary Care: Family Medicine, General Practice, Internal Medicine, Pediatrics, and APRNs carrying a primary care panel of attributed lives

END OF LIFE CARE FOR CANCER PATIENTS

Measure Objective	Improve quality of life at end of life, and optimize oncological services for patients by improving access to more appropriate care at the end of life
Description	Proportion of patients who passed away with a diagnosis of cancer with one or more emergency department visits in the last 30 days of life
Points	1
Program	SSP
Numerator	Patients who passed away with cancer and had one or more emergency department visits in the last 30 days of life
Denominator	Patients who passed away with cancer during the measurement year
Exclusions	N/A
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	Overall HHP aggregate score at or below 30%
Eligible Members	Specialists: Hematology/Oncology
How to Meet the Measure	The cancer care team should work to prevent emergency department visits by educating patients about options for end of life care

MAMMOGRAM IMAGING CALLBACK RATES

Measure Objective	Improve patient experience by reducing variation in mammogram imaging callback rates
Description	The frequency that patients are asked to come back for additional images from screening
Points	1
Program	SSP
Numerator	Number of mammograms identified as needing additional imaging evaluation
Denominator	Total number of mammograms performed
Exclusion	N/A
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	≤14%*
	Specialists: Aggregate score by facility at or below 14%
	*Carney PA, Sickles EA, Monsees BS, et al. Identifying Minimally Acceptable Interpretive Performance Criteria for Screening Mammography. Radiology. 2010;255(2):354-361. doi:10.1148/radiol.10091636.
Eligible Members	Specialists: Radiology

NATIONAL IMAGING ASSOCIATES (NIA) / MAGELLAN PRIOR AUTHORIZATIONS

Measure Objective	Improve patient and provider experience by streamlining prior authorization process, and improve appropriateness of ordering advanced diagnostic imaging studies	
Description	Percentage of clinically appropriate imaging studies ordered	
Points	Maximum points possible are based on total order volume: ≤5 orders = 0.5 point >5 orders = 1 point	
Program	SSP	
Numerator	Number of advanced diagnostic imaging studies ordered appropriately	
Denominator	Total advanced diagnostic imaging studies ordered by the provider and reviewed by NIA/ Magellan	
Exclusion	N/A	
Measurement Period	January 1, 2020 - December 31, 2020	
Performance Target	t ≥95%	
	Individual score at or above 95%	
Eligible Members	Primary Care: Family Medicine, General Practice, Internal Medicine, Pediatrics, and APRNs carrying a primary care panel of attributed lives	
	Specialists: All ordering providers	
	Excludes non-NIA participating providers, including, but not limited to, Anesthesiology, Critical Care Medicine, Diagnostic Radiology, Emergency Medicine, Hospitalists, Interventional Radiology, Medical Genetics, Neuroradiology, Nuclear Medicine, Occupational Medicine, Pathology	
How to Meet the Measure	To learn how to use the clinical decision software to improve ordering appropriateness, providers can view the 2020 HHP NIA/Magellan Prior Authorizations learning module on the HPH Learning Center (HLC). Contact Info@hawaiihealthpartners.org if you have questions.	

NSAID UTILIZATION IN CKD PATIENTS

Measure Objective	Reduce the incidence of acute kidney injury in patients with Chronic Kidney Disease (CKD) by avoiding nonsteroidal anti-inflammatory drugs (NSAIDS) in individuals with CKD
Description	Avoid ordering NSAIDs in individuals with a diagnosis of CKD stage 3-5, OR whose most recent serum creatinine in the last year is greater than or equal to 2.0, OR whose most recent eGFR in the last year is less than 60.
	This measure is intended to alert providers of patients who have CKD and the potential harm of NSAIDS worsening renal dysfunction. Providers should consider alternative medication options when medically appropriate. Clinical judgement takes precedence.
Points	1
Program	SSP
Performance Measurement	An applicable NSAID order for this measures is a medication order of an oral or intravenous NSAID for patients 18 years of age or older with: • a diagnosis of CKD stage 3-5
	or • serum creatinine in the last year greater than or equal to 2.0 or • eGFR in the last year less than 60
	Inpatient & ED: Includes intravenous administration & oral medications Ambulatory: Includes only oral medications
Exclusions	Medication frequency is set as a one time or PRN orderPatients diagnosed with gout
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	 Provider will earn credit in one of two ways: Five or less applicable NSAID orders in 2020 or 50% reduction in applicable NSAID orders compared to 2019
Eligible Members	All ordering physicians (includes all specialties other than those excluded below) and APRNs carrying a primary care panel of attributed lives with a minimum of five Epic encounters with a CKD patient meeting the criteria in the performance measurement.
	Excludes Diagnostic Radiology, Interventional Radiology, Medical Genetics, Neuroradiology, Nuclear Medicine, and Pathology
How to Meet the Measure	HHP will email providers their 2019 performance via Info@hawaiihealthpartners.org. For more information, contact HHP at Info@hawaiihealthpartners.org.

OSTEOPOROSIS MANAGEMENT IN WOMEN WHO HAD A FRACTURE

Measure Objective	Encourage appropriate treatment following a fracture	
Description	Percentage of women 67 to 85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture	
Points	1	
Program	SSP	
Numerator	Patients from the denominator who received either a BMD test or a prescription for a drug to treat osteoporosis in the six months after the fracture	
	BMD test must take place within six months of the fracture. If the fracture resulted in an inpatient stay, a BMD test administered during the stay will satisfy the measure.	
	Osteoporosis therapies will be identified through pharmacy data. Osteoporosis medication within six months of the fracture will satisfy the measure. Patients will not be excluded if the medications aren't tolerated. If the fracture resulted in an inpatient stay, long-acting osteoporosis therapy administered during the stay will satisfy the measure.	
Denominator	HMSA Commercial, Akamai, and Essential Advantage attributed female patients, 67 to 85 years of age, who experienced a fracture (except fractures of the finger, toe, face or skull)	
Exclusions	Patients who had a BMD test 24 months prior to the fracture	
	Patients who had osteoporosis therapy 12 months prior to the fracture	
	 Patients who were dispensed a medication or had an active prescription for medication to treat osteoporosis 12 months prior to the fracture 	
	Patients in hospice anytime during the measurement year	
	 Patients living in long-term care institutions or enrolled in an Institutional SNP (I-SNP) anytime during the measurement year 	
	• Patients age 81 and older as of January 1 of the measurement year with frailty	
Measurement Period	January 1, 2020 - December 31, 2020	
	Patients with fractures: September 1, 2019 - August 31, 2020	
Performance Target	Overall HHP aggregate score at or above 80%	
Case Threshold	1	
	continued on next page	

OSTEOPOROSIS MANAGEMENT IN WOMEN WHO HAD A FRACTURE

Eligible Members	Primary Care Providers on Epic: Family Medicine, General Practice, Internal Medicine, and APRNs carrying a primary care panel of attributed lives			
How to Meet the Measure	Appropriate medical re - Medication list - Progress notes - BMD test results	ecord detail of any of the following:		
	BMD test			
	- BMD test must take p	place within six months of the fracture		
		d in an inpatient stay, a BMD test adm	ninistered during the stay will close	
	the care gap. Providers should us	se the following codes:		
	Providers should use the following codes: CPT/CPT II: 76977, 77078, 77080, 77081, 77082, 77085, 77086 HCPCS: G0130		77086	
	ICD-10 Procedure: E	3P48ZZ1, BP49ZZ1, BP4GZZ1, BP4HZ , BQ01ZZ1, BQ03ZZ1, BQ04ZZ1, BR(
	Osteoporosis therapies			
	- Osteoporosis medication must be dispensed within six months of the fracture.			
	 Documentation that the medications aren't tolerated isn't an exclusion for this measure. If the fracture resulted in an inpatient stay, long-acting osteoporosis therapy administered 			
	during the stay will close the care gap.			
	Providers should use the following codes: HCPCS: J0630, J0897, J1740, J3110, J3489			
	HCPCS: J0630, J08	97, J1740, J3110, J3489		
		Bd		
	Drug category Biphosphonates	Medications • Albandronate	• Ibandronate	
	Dipliosphonates	Alendronate	Risedronate	
		Alendronatecholecalciferol	• Zoledronic acid	
	Other agents	Calcitonin	• Raloxifene	
		Denosumab	• Teriparatide	
	See HMSA Formulations at l	hmsa.com/help-center/your-hmsa-drug-formula	ry-list.	

POSTPARTUM CARE

Measure Objective	Encourage postpartum visits to improve maternal and perinatal health outcomes
Description	Percentage of deliveries that had a postpartum visit on or between 7 and 84 days after delivery
Points	1
Program	SSP
Numerator	Patients from the denominator with a postpartum visit for a pelvic exam or postpartum care on or between 7 and 84 days after delivery
Denominator	Number of HMSA Commercial and Quest attributed patients who delivered live births on or between November 6 of the year before the measurement year and November 5 of the measurement year
Exclusions	Patients whose OB/GYN is not an HHP member
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	Primary Care & Specialists: Overall HHP aggregate score at or above 50%
Case Threshold	Primary Care: 5 or more patients who fall into the denominator
	Specialists: None
Eligible Members	Primary Care: Family Medicine, General Practice, Internal Medicine, Pediatrics, and APRNs carrying a primary care panel of attributed lives with 5 or more patients who fall into the denominator
	Specialists: Obstetrics & Gynecology, Gynecology
How to Meet the Measure	For information on codes for maternity services, please refer to hmsa.com/portal/provider/zav_pel.ph.pre.650.htm

CARE DELIVERY

PRENATAL CARE

Measure Objective	Reduce the risk of pregnancy complications and improve the chances of a healthy pregnancy
	Reduce the risk of pregnancy complications and improve the chances of a healthy pregnancy
Description	Percentage of deliveries that received a prenatal care visit as an HMSA attributed patient in the first trimester, on the enrollment start date or within 42 days of enrollment
Points	1
Program	SSP
Numerator	Patients from the denominator with a prenatal visit in the first trimester
Denominator	Number of HMSA Commercial and Quest attributed patients who delivered live births on or between November 6 of the year before the measurement year and November 5 of the measurement year and whose OB/GYN received the HMSA global maternity fee
Exclusions	Patients whose OB/GYN is not an HHP member
Measurement Period	January 1, 2020 - December 31, 2020
Performance Target	Primary Care & Specialists: Individual score at or above 90%
Case Threshold	Primary Care: 5 or more patients who fall into the denominator
	Specialists: None
Eligible Members	Primary Care: Family Medicine, General Practice, Internal Medicine, Pediatrics, and APRNs carrying a primary care panel of attributed lives with 5 or more patients who fall into the denominator
	Specialists: Obstetrics & Gynecology, Gynecology
How to Meet the Measure	For information on codes for maternity services, please refer to hmsa./com/portal/provider/zav_pel.ph.pre.650.htm

Measure Objective	Encourage the use of technology to support provider-to-provider communication via Epic	
Description	Provider-to-provider consults completed via Epic	
Points	1	
Program	SSP	
Numerator	Total number of provider-to-provider consults* completed via Epic in the measurement year	
	*An eConsult sent or received by a provider in Epic will count as one provider-to-provider consult.	
Denominator	N/A	
Exclusions	N/A	
Measurement Period	January 1, 2020 - December 31, 2020	
Performance Target	10 provider-to-provider consults completed via Epic	
Eligible Members	All participating providers	
How to Meet the Measure	Use Epic eConsults function to complete provider-to-provider consults	

PROVIDER USE OF MYCHART EVISITS

Measure Objective	Encourage the use of technology to support patient-provider communication via MyChart and improve patient experience and access		
Description	Patient encounters completed via MyChart eVisits		
Points	1		
Program	SSP		
Numerator	Total number of eVisit patient encounters completed via MyChart in the measurement year		
Denominator	N/A		
Exclusions	N/A		
Measurement Period	January 1, 2020 - December 31, 2020		
Performance Target	25 eVisit patient encounters completed via MyChart		
Eligible Members	Primary Care: Family Medicine, General Practice, Internal Medicine, Pediatrics, and APRNs carrying a primary care panel of attributed lives		
How to Meet the Measure	Complete patient encounters via MyChart eVisits. To learn how to utilize eVisits, providers can view the 2019 HHP MyChart learning module on the HPH Learning Center (HLC). Contact Info@hawaiihealthpartners.org if you have questions:		

38 o E-Prescribing Error Messages Results Addendum Chart Cosign Cosign - Clinic

SSP

CARE DELIVERY

REFERRAL OF HIGH RISK PATIENTS TO HHP COMPLEX CARE PROGRAM

Measure Objective	Improve management of high risk patients, via enrollment in HHP Complex Care Program, with the aim of bettering patient engagement, clinical outcomes and satisfaction, and reducing the projected cost of care	
Description	Primary Care Provider (Internal Medicine, Family Medicine, General Practice, APRNs carrying a primary care panel of attributed lives) to refer patients classified as High Risk or Very High Risk per Epic Risk Stratification classification, with at least 3 referrals ultimately enrolling in the HHP Complex Care Program	
Points	1	
Program	SSP	
Numerator	High Risk or Very High Risk patients referred to, and enrolled in, the HHP Complex Care Program	
Denominator	HMSA Commercial patients classified as High Risk or Very High Risk per Epic Risk Stratification	
Exclusions	N/A	
Measurement Period	January 1, 2020 - December 31, 2020	
Performance Target	Primary Care Provider referral of High Risk or Very High Risk patients to HHP Complex Care via established referral process with 3 of these patients successfully enrolled in the HHP Complex Care program	
Eligible Members	Primary Care: Internal Medicine, General Practice, Family Medicine, and APRNs carrying a primary care panel of attributed lives with ≥400 HMSA Commercial attributed patients	
How to Meet the Measure	Step 1: Check that the patient is high risk or adjust the patient (see below).	
	Step 2: At least 3 patients must enroll to meet the measure.	

Epic Risk Score

SnapShot	Rooming Sovering Charl Complant Vital Stats Carr Environment Review Adaptes Verify Ro Bindits Here Mindpatent Honoy III Infection Screening /	October Media D. Adjusted Risk Score > Dyslician Adjusted Risk Score > Physician Adjusted Risk Score > Physician Adjusted Risk Score > Physician Adjusted Risk Score >	7
Care Everywh	Area Reading Infection Screening Index year of the diff in the past month?	Powenest /	_
Screensificur.	P Chief Complaint //	General Risk Score List DPoints (parties drank) conditions 4 1-8 Parties May New York Conditions with the Mark May New York Conditions when complications with the Mark May New York Conditions with complications with the Conditions The Mark May New York Conditions 2 Ager 35 Parties age 63- a 1 points List Condition Conditions Barliets age 63- a 1 points List Condition Conditions Conditio	t age 71
Wrap-Up	★ Vital Signs / ↓ New Set of Vatas	Ofisal Choolic Obstructive Pulmonary Disease: No Paiate's points Paiate's points isst indiated 8 minutes ann	,

USE OF HIGH RISK MEDICATIONS IN THE ELDERLY

Measure Objective	Reduce adverse outcomes by avoiding high-risk medications for patients 65 years of age and older	
Description	Avoid ordering high-risk medications for patients 65 years of age and older (e.g., anticholinergics [excluding TCAs], barbiturates, long-acting sulfonylureas, etc.) whose route is oral, transdermal, or rectal. The measure is intended to alert providers of patients who are 65 years of age and older to consider alternative medication options when medically appropriate. Clinical judgement takes precedent.	
Points	1	
Program	SSP	
Numerator	Patients who were ordered at least one high-risk medication during the measurement period	
Denominator	Patients 65 years and older who had a visit during the measurement period	
Exclusion	Non-Epic providers	
Measurement Period	January 1, 2020 - December 31, 2020	
Performance Target	Provider will earn credit in one of two ways:	
	 ≤20 applicable high-risk medication orders in 2020 	
	or • 50% reduction in applicable high-risk medication orders compared to 2019	
Case Threshold	100 Epic encounters with a patient 65 years of age or older	
Eligible Members	All ordering physicians (includes all specialties other than those excluded below) and APRNs carrying a primary care panel of attributed lives	
	Excludes Diagnostic Radiology, Interventional Radiology, Maternal & Fetal Medicine, Medical Genetics, Neuroradiology, Nuclear Medicine, Pathology, and Repro Endocrin/Infertility. Excludes non-Epic providers.	
How to Meet the Measure	HHP will email providers their 2019 performance via Info@hawaiihealthpartners.org. For more information, contact HHP at Info@hawaiihealthpartners.org.	

USE OF HHP DASHBOARD

Measure Objective	Support effective population health management by encouraging the evaluation of patient data through the use of the HHP Dashboard by Primary Care Providers		
Description	Access and use of the HHP Dashboard for population health management		
Points	1		
Program	SSP		
Inclusion	All PCPs with an active HHP Dashboard account by October 1, 2020		
Exclusion	N/A		
Measurement Period	January 1, 2020 - December 31, 2020		
Performance Target	Provider must log in to dashboard at least once per month for at least 10 months of the measurement period OR if a provider joined HHP during the measurement period, at least 80% of the months dashboard was active.		
Eligible Members	Primary Care: Internal Medicine, General Practice, Family Medicine, Pediatrics, and APRNs carrying a primary care panel of attributed lives		
How to Meet the Measure	The HHP Dashboard is available in Epic.		
	Health Advantage Connect (HAC) providers should log into portal.hawaiipacifichealth.org to access the HHP Dashboard in Epic.		
	HHP Dashboard (all providers)		
	Provider Reporting Homepage Hawaii Health Partners (HHP) Just now The HHP dashboard - Personal Provider Reporting Homepage If you have questions, please e-mail pepdashboard@hawaiihealthpartners.org or coll 522-3163. HHP Primary Care Physician Dashboard HHP Internet Site		

COMPENSATING SPECIALISTS SHARED SAVINGS PROGRAM

For purposes of compensating specialists based on their potential to generate shared savings, the following Tier Multiplier is used for calculating Shared Savings distribution.

Tier Multiplier = 5.0

Tier Multiplier = 5.0		
Tier Name	Specialties	
Targeted Initiatives	 Cardiology Emergency Medicine Endocrinology Geriatric Medicine Gynecology Hospice and Palliative Medicine Hospitalist – Family Medicine 	 Hospitalist – Internal Medicine Hospitalist – Pediatrics Nephrology Obstetrics & Gynecology Pediatric Emergency Medicine Pulmonology
Tier Multiplier = 2.0		
Tier Name	Specialties	
Population Health	 Adolescent Medicine (non-PCP) Cardiac Electrophysiology Clinical Psychology Critical Care Medicine Diagnostic Radiology Family Medicine (non-PCP) Gastroenterology General Practice (non-PCP) General Surgery Gynecologic Oncology Hematology/Oncology Infectious Disease Internal Medicine (non-PCP) Interventional Radiology Maternal & Fetal Medicine Medical Oncology Neurology Neuroradiology Neurosurgery Ophthalmology Orthopedic Surgery Otolaryngology Pediatric Critical Care 	 Pediatric Endocrinology Pediatric Gastroenterology Pediatric Hematology/Oncology Pediatric Infectious Diseases Pediatric Nephrology Pediatric Neurology Pediatric Pulmonology Pediatric Rheumatology Pediatric Sports Medicine Pediatric Urology Pediatrics (non-PCP) Physical Medicine & Rehab Plastic Surgery Psychiatry Radiation Oncology Surgical Oncology Surgical Oncology Thoracic Surgery Urgent Care/Walk-In Urogynecology & Pelvic Reconstruction Urology Vascular Surgery
Tier Multiplier = 1.0		
Tier Name	Specialties	
Foundational	Allergy & ImmunologyAnesthesiology	 Nuclear Medicine Occupational Medicine

- Dermatology
- Dermatopathology
- Developmental-Behavioral Peds
- Medical Genetics

- Occupational Medicine
- Pathology
- Podiatry
- Sleep Medicine
- Sports Medicine

Creating a healthier Hawai'i



CREATING A HEALTHIER HAWAI'I

1100 Ward Ave. Suite 670 • Honolulu, Hawai'i 96814 HawaiiHealthPartners.org